World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT01499667
Date of registration: 18/08/2011
Prospective Registration: Yes
Primary sponsor: Novartis Pharmaceuticals
Public title: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod TOFIINGO
Scientific title: A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)
Date of first enrolment: September 2011
Target sample size: 142
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/show/NCT01499667
Study type:  Interventional
Study design:   
Phase:  Phase 3
Countries of recruitment
Australia Austria Czech Republic Finland Germany Greece Hungary Israel
Italy Spain Switzerland
Contacts
Name:     Novartis Pharmaceuticals
Address: 
Telephone:
Email:
Affiliation:  Novartis Pharmaceuticals
Key inclusion & exclusion criteria

Inclusion Criteria:

Patients must:

- Have relapsing remitting multiple sclerosis

- Have been on treatment with natalizumab for at least 6 months prior to screening and
discontinuation is an option.

Exclusion Criteria:

Patients with:

- History of chronic immune disease

- Crohn's disease

- Certain cancers

- Uncontrolled diabetes

- Certain eye disorders

- Negative for varicella-zoster virus IgG antibodies

- Certain hepatic conditions

- Low white blood cell count

- On certain immunosuppressive medications or heart medications

- Resting heart rate less than 45 bpm.

- Certain heart conditions or certain lung conditions

- Inability to undergo MRI scans

Other protocol-defined inclusion/exclusion criteria may apply



Age minimum: 18 Years
Age maximum: 65 Years
Gender: All
Health Condition(s) or Problem(s) studied
Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention(s)
Drug: Fingolimod
Drug: Placebo
Primary Outcome(s)
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment [Time Frame: Number of active T2 lesions from last natalizumab dose through 8 weeks of fingolimod treatment]
Secondary Outcome(s)
Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline) [Time Frame: Baseline up to 24 weeks]
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment [Time Frame: 8, 12 and 16 weeks (number of active T2 lesions during the washout period only)]
Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group [Time Frame: Baseline to week 16 and week 32]
Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion [Time Frame: 8 weeks and 24 weeks]
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period [Time Frame: Baseline to maximum of 16 weeks]
Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment [Time Frame: Number of active T2 lesions during 8 wks of fingolimod treatment]
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment [Time Frame: Baseline to maximum of 16 weeks]
Secondary ID(s)
2011-001442-15
CFTY720D2324
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 04/04/2014
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01499667
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey